Joel Farley, PhD
PhD, University of Minnesota, Social and Administrative Pharmacy, 2006
BS, Pharmacy, University of Wisconsin – Madison, 1997
Dr. Farley is a pharmacist and pharmaceutical outcomes researcher specializing in the evaluation of programs and policies affecting medication use in patients with chronic health conditions. Dr. Farley has expertise conducting research using secondary medical claims data including federal data sets (e.g. Medicaid and Medicare), commercial claims data sources (e.g. Blue Cross Blue Shield and MarketScan), and publicly available data sources (Medicare Current Beneficiary Survey, Medical Expenditure Panel Survey, and SEER-Medicare).
Clinical Experience Statement
Dr. Farley is a licensed pharmacist in New Mexico (active) and Minnesota (inactive). His direct patient care experience involved practice solely in the community pharmacy setting.
- Smith MG, Shea CM, Brown P, Wines K, Farley JF, Ferreri SP. (2017) “Pharmacy characteristics associated with the provision of medication management services within an integrated care management program.” Journal of the American Pharmacists Association 57(2):217-221.
- Farley JF, Hansen RA, Domino ME, Borse M, Mahendraratnam N, Ray N, Maciejewski ML. (2017) “Continuity of Medication Management in Medicaid Patients with Chronic Comorbid Conditions: An Examination by Mental Health Status” Journal of General Hospital Psychiatry. 45(2017):25-31.
- Roberts AW, Farley JF, Holmes M, Oramasionwu CU, Sleath B, Ringwalt C, Skinner A. (2016) “Controlled substance lock-in programs: Examining an unintended consequence of a prescription drug abuse policy.” Health Affairs. 35(10):1884-1892.
- Mahendraratnam N, Dusetzina SB, Farley JF. (2017) “Prescription drug utilization and reimbursement increased following state Medicaid expansion in 2014”. Journal of Managed Care Pharmacy. 23(3):355-363.
- Roberts AW, Dusetzina SB, Farley JF. (2015) “Revisiting the washout period in the incident user study design: Why 6 to 12 months may not be sufficient” Journal of Comparative Effectiveness Research. 4(1):27-35.
- Maciejewski ML, Wansink D, Lindquist JH, Parker JC, Farley, JF. (2014) “Value-Based Insurance Design Program In North Carolina Increased Medication Adherence But Was Not Cost Neutral” Health Affairs. 33(2):300-308.
- Farley JF, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. (2012) “Medication Adherence Changes following Value Based Insurance Design (VBID)” American Journal of Managed Care. 18(5):41-50.
- Hansen RA, Maciejewski ML, Yu-Isenberg K, Farley JF. (2012) “Adherence to antipsychotics and cardiometabolic medication association with health care utilization and costs.” Psychiatric Services. 63(9):920-928
- Farley JF, Wang CC, Hansen RA, Voils CI, Maciejewski ML. (2011) “Continuity of Antipsychotic Medication Management for Medicaid Patients with Schizophrenia” Psychiatric Services. 62(7):747-752.
- Farley JF, Harley CR, Devine JW. (2006) “A comparison of comorbidity measurements to predict health expenditures.”American Journal of Managed Care. 12(2): 110-117.